Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteers test devices that boost leg circulation

NCT ID NCT06590610

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how two devices—a radial pressure wave device (RPW2) and a TENS unit—temporarily change blood flow in the lower leg. Twenty healthy adults in the UK received both treatments, and their blood flow was measured with ultrasound before, during, and after each session. The goal was to gather safety and performance data, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Sep 2024

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects, both male and female, ≥ 18 years of age at the time of consent. 2. Subject is available to attend all study appointments for the study duration 3. Any Subject who has reviewed the IEC-approved consent form, has been properly consented per the protocol and has documented their consent to participate in the study by signing the Ethics-approved consent form. Exclusion Criteria: 1. Subjects with any cognitive impairment who prevent to understand the information provided and freely and autonomously provide and sign informed consent to participate in the study. 2. Subject is pregnant or has plans of becoming pregnant for the duration of the study. 3. Presence of cancerous tumours/Neoplastic tissue/lesions in treatment area (back lower limb of both legs) 4. Subject possesses a prosthetic lower limb 5. Diagnosed with diabetes 6. Cortisone therapy ongoing or within the last 6 months before treatment 7. Diagnosed Haemophilia, Thrombosis, Deep vein thrombosis, phlebitis, varices, risk of haemorrhage, occlusive vascular disease or other coagulation disorders 8. Treatment with anticoagulant pharmaceuticals 9. Reduced sensitivity over the proposed area of treatment (back lower limb of both legs) 10. Suspected or diagnosed cardiopathy 11. Any history of cardiovascular disease e.g., cardiac arrhythmia and angina pectoris, arterial disease, circulatory insufficiency. 12. Implanted electronic devices e.g., cardiac stimulator, implanted defibrillator or other implanted electronic/electrical device 13. Hypertension (\> stage 2), ischemic heart disease and cerebrovascular diseases 14. Peripheral vascular disease or serious arterial or venous circulation problems in any of the lower limbs. 15. Systemic or local infection. 16. Open wounds, rashes, swollen, red, infected, inflamed areas or skin eruptions at the site of treatment (back lower limb of both legs). 17. Diagnosis of Epilepsy or has had any previous Epileptic episodes. 18. Proven allergy to the study devices materials or electrodes. 19. Recent surgery or metal implant present at the site of treatment (back lower limb of both legs)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Whiteley Clinic

    Guildford, GU2 7RF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.